Aratana Therapeutics, Inc. (NASDAQ:PETX) - Research analysts at William Blair boosted their FY2019 earnings estimates for Aratana Therapeutics in a research report issued on Wednesday. William Blair analyst J. Kreger now expects that the biopharmaceutical company will post earnings per share of $0.36 for the year, up from their previous estimate of $0.35.
Several other analysts have also issued reports on the company. Jefferies Group LLC reissued a “buy” rating and set a $8.00 target price on shares of Aratana Therapeutics in a report on Friday, May 5th. ValuEngine lowered Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 31st. Stifel Nicolaus reduced their target price on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Zacks Investment Research lowered Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, BidaskClub lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $10.00.
WARNING: “Aratana Therapeutics, Inc. (NASDAQ:PETX) to Post FY2019 Earnings of $0.36 Per Share, William Blair Forecasts” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/09/aratana-therapeutics-inc-nasdaqpetx-to-post-fy2019-earnings-of-0-36-per-share-william-blair-forecasts-updated.html.
Shares of Aratana Therapeutics (NASDAQ:PETX) opened at 6.87 on Friday. The stock has a 50 day moving average of $7.04 and a 200 day moving average of $6.50. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $10.73. The firm’s market cap is $260.76 million.
Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34). Aratana Therapeutics had a negative net margin of 66.72% and a negative return on equity of 14.95%. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $3.05 million. During the same quarter in the previous year, the company earned ($0.52) EPS. The firm’s revenue for the quarter was up 2135.3% compared to the same quarter last year.
A number of hedge funds have recently added to or reduced their stakes in PETX. Vanguard Group Inc. raised its stake in Aratana Therapeutics by 13.9% in the first quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock valued at $10,211,000 after buying an additional 235,208 shares during the period. Wells Fargo & Company MN raised its stake in Aratana Therapeutics by 281.4% in the first quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 203,738 shares during the period. Tocqueville Asset Management L.P. raised its stake in Aratana Therapeutics by 56.3% in the first quarter. Tocqueville Asset Management L.P. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,325,000 after buying an additional 90,000 shares during the period. Dimensional Fund Advisors LP raised its stake in Aratana Therapeutics by 85.7% in the first quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 59,181 shares during the period. Finally, AWM Investment Company Inc. raised its stake in Aratana Therapeutics by 5.7% in the first quarter. AWM Investment Company Inc. now owns 1,062,620 shares of the biopharmaceutical company’s stock valued at $5,632,000 after buying an additional 57,620 shares during the period. 68.08% of the stock is currently owned by institutional investors and hedge funds.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
